Home > Journals > Minerva Psichiatrica > Past Issues > Minerva Psichiatrica 2010 December;51(4) > Minerva Psichiatrica 2010 December;51(4):263-9



To subscribe
Submit an article
Recommend to your librarian





Minerva Psichiatrica 2010 December;51(4):263-9


language: English

A double-blind placebo-controlled trial of bupropion for smoking abstinence and cognition improvement in schizophrenia

Akbarpour F. 1, Rezaei O. 1, Khodaie-Ardakani M. R. 1, Sheikhvatan M. 2, Goodarzi H. 2, Dolatshahi B. 1

1 Razi Psychiatric Hospital, University of Social Welfare and Research Sciences, Tehran, Iran 2 Research Department, Tehran Heart Center, Tehran University of Medical Sciences,Tehran, Iran


Aim. The efficacy and tolerability of Bupropion as a non-nicotine-based therapeutic protocol for smoking discontinuation, and for improving impaired cognition in schizophrenia has already been reported. The current study tests the efficacy and safety of bupropion for smoking cession, and for improvement of cognition among a sample of Iranian hospitalized patients with schizophrenia.
Methods. In a double-blind, placebo-controlled trial, 32 schizophrenic smokers were randomly assigned to receive bupropion (N.=16), delivered according to the standard therapeutic dose (150 mg/day for the first three days, followed by 300 mg/day), or matching placebo (N.=16), administered orally for a total of 8 weeks. Primary outcome measures were continuous smoking abstinence (change the number of smoked cigarette) and also severity of cognitive impairment based on Mini-mental state examination (MMSE) test.
Results. Although smoking abstinence was found similar in bupropion and placebo group before the treatment protocols, bupropion group abstain the smoking more than the placebo group at the end of the treatment approaches. Mean baseline MMSE score was similar in the two groups, while patients treated with bupropion had significantly higher MMSE score at the end of the medication. The severity of cognitive impairment was significantly reduced following bupropion administration. Bupropion therapy was effective therapeutic protocol in cognitive enhancement and also smoking discontinuation in schizophrenic after adjusting for patients’ age and weight, marital status, education level and duration of disease.
Conclusion. Similar to western countries, bupropion therapy is effective for increasing smoking abstinence as well as improving cognitive impairments in Iranian schizophrenic smokers.

top of page